TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15242865
Drug: IFN beta
Normalized name: IFN beta2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta 44 microg (0.5 ml)
Study: 15242865
Drug: Placebo (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.05 ml or 0.5 ml)
Study: 593192
Drug: gestonoroncapronate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gestonoroncapronate (600 mg/week)
Study: 28928195
Drug: Baby mCIMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby mCIMT (modified constraint‐induced movement therapy)
Study: 28928195
Drug: Baby BIM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby BIM (bimanual therapy)
Study: 17229239
Drug: Histamine‐2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine‐2 receptor antagonists
Study: 17229239
Drug: Alginate/antacid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate/antacid combination
Study: 11689731
Drug: Walking activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking activity (3 km/d above daily lifestyle walking)
Study: 9244939
Drug: 0.04% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% bupivacaine plus adrenalin 1/2,500,000 and fentanyl 2.5 micrograms/ml (Group II)
Study: 9244939
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine plus adrenalin 1/1,600,000 and fentanyl 2 micrograms/ml (Group III)
Study: 7706602
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg beta-carotene
Study: 7706602
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg canthaxanthin
Study: 7706602
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg beta-carotene and 25 mg canthaxanthin (combined dose)
Study: 1161368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of systematic preparation, rehearsal, and supportive care conducted prior to each stressful procedure
Study: 1161368
Drug: Single-session preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session preparation conducted after admission
Study: 1161368
Drug: Consistent supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent supportive care given by one nurse at the same points as in the first condition, but including no systematic preparation or rehearsal
Study: 30981618
Drug: Neodymium: yttrium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodymium: yttrium aluminum garnet laser treatment
Study: 22097347
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) (three pills, tid)
Study: 22097347
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three pills, tid)
Study: 22429128
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release doxycycline gel (SRD) administered adjunctively to subgingival ultrasonic/sonic instrumentation (USI)
Study: 22429128
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release doxycycline gel (SRD)
Study: 2798445
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day aspirin
Study: 2798445
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day aspirin
Study: 11442187
Drug: Brimonidine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine as adjunctive therapy
Study: 11442187
Drug: Brimonidine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine added to nonselective beta-blocker monotherapy
Study: 11442187
Drug: Brimonidine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine added to latanoprost monotherapy
Study: 11442187
Drug: Brimonidine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine added to combination regimens including latanoprost
Study: 11442187
Drug: Physician rating
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician rating of brimonidine adjunctive therapy
Study: 8062504
Drug: 3-hydroxybutyrate infusion
Normalized name: 2-Amino-3-hydroxybutyric acid
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hydroxybutyrate infusion
Study: 10195546
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg/kg
Study: 15310636
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL saline (placebo)
Study: 12213884
Drug: rhIGF‐I (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (30 μg/kg·d) for 1 yr
Study: 12213884
Drug: 100 μg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg/L IGF‐I (13 nM)
Study: 70585
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid (600 mg/day)
Study: 70585
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid (150 mg/day)
Study: 15668544
Drug: EFV 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV 600 mg once daily
Study: 23294034
Drug: AZV/r 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZV/r 300 mg and ritonavir 100 mg once daily
Study: 23294034
Drug: LPV/r 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 400 mg and ritonavir 100 mg twice daily
Study: 21812910
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of ketamine 1 mg/kg (Group KS1)
Study: 21812910
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of ketamine 2 mg/kg (Group KS2)
Study: 21812910
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 1 mg/kg (Group KI)
Study: 21812910
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of normal saline 20 mL (Group C)
Study: 18194386
Drug: MBL deficiency
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBL deficiency (MBL ≤ 80 ng/mL)
Study: 16472564
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 - Initial injection on 1st-5th day of menstrual cycle, subsequent injections every 30 +/- 3 days.
Study: 16472564
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 - Initial injection between Days 7 and 10 of menstrual cycle, subsequent injections 7-10 days after Day 1 of withdrawal bleeding.
Study: 10473015
Drug: Frequent testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent testing (twice per week) for 10 weeks
Study: 10473015
Drug: Less frequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less frequent testing (approximately weekly or every 3-4 weeks)
Study: 25741816
Drug: Ocriplasmin 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin 125 μg
Study: 16493123
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (450 mL daily, 40 grams of alcohol)
Study: 16493123
Drug: De-alcoholized red
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-alcoholized red wine (450 mL daily)
Study: 27164691
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (1,000 IU orally twice daily for 3 years)
Study: 16627836
Drug: Nebulisation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulisation with a combination of salbutamol (0.5 mg) and magnesium sulphate (500 mg)
Study: 16627836
Drug: Nebulisation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulisation with salbutamol only (0.5 mg)
Study: 11903240
Drug: Emulsifying ointments
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emulsifying ointments (unguentum emulsificans and dilutions with 30, 50, 70 and 90% aqua purificans)
Study: 9860106
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg and 4 mg
Study: 9860106
Drug: Flunitrazepam (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (various doses)
Study: 2198165
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT) at increasing doses (50-1,500 mg)
Study: 2198165
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT) at daily 3,000 mg doses for 1 week
Study: 320654
Drug: Ampicillin pediatric
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin pediatric suspension (100 mg ampicillin/kg/24 hours divided in 4 doses)
Study: 320654
Drug: Pivampicillin base
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin base pediatric suspension (64.8 mg/kg/24 hours divided in 4 doses)
Study: 23489888
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (aspirin 75‐160 mg daily and clopidogrel 300 mg day 1 then 75 mg daily)
Study: 23489888
Drug: Monotherapy (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (aspirin 75‐160 mg daily)
Study: 22829901
Drug: Digested PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digested PR preparations
Study: 17612824
Drug: Individual Brief
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Brief Therapeutic Phone Contacts (IBTPC) integrating motivational interviewing and cognitive behavioral therapies
Study: 15197430
Drug: Polymyxin B-immobilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-immobilized fiber (PMX-F) treatment (n=15)
Study: 15197430
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n=10)
Study: 12076241
Drug: Hormone/estrogen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone/estrogen replacement therapy (H/ERT)
Study: 9874467
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa administration for patients receiving cisplatin chemotherapy
Study: 9874467
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa administration for patients receiving noncisplatin chemotherapy
Study: 7622259
Drug: 5-day antibacterial
Normalized name: chloroxylenol 5 MG/ML [QSR Antibacterial]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day antibacterial therapy (Penicillin 300 mg/kg for meningococcal and pneumococcal meningitis; Ampicillin 300 mg/kg for Haemophilus influenzae b meningitis)
Study: 7622259
Drug: 5-day antibacterial
Normalized name: chloroxylenol 5 MG/ML [QSR Antibacterial]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day antibacterial therapy
Study: 7622259
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (8 to 15 days of antibacterial therapy)
Study: 31357534
Drug: Functional VOO
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional VOO enriched with olive oil PCs (500 mg/kg)
Study: 31357534
Drug: Functional VOO
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT)
Study: 31357534
Drug: Natural VOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural VOO (control intervention; olive oil PCs: 80 mg/kg)
Study: 26110375
Drug: Naloxone sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone sustained release (NSR) 2.5 mg
Study: 26110375
Drug: Naloxone sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone sustained release (NSR) 5 mg
Study: 26110375
Drug: Naloxone sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone sustained release (NSR) 10 mg
Study: 26110375
Drug: Naloxone sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone sustained release (NSR) 20 mg
Study: 19671333
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) therapy, n = 70
Study: 9392401
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate
Study: 12194936
Drug: Riboflavin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (1.6 mg/day)
Study: 2171846
Drug: Guanadrel sulfate
Normalized name: guanadrel sulfate
DrugBank: Guanadrel (DB00226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guanadrel sulfate (3 weeks treatment)
Study: 2171846
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 weeks treatment)
Study: 619817
Drug: Carmustine and
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine and fluorouracil (two-drug regimen)
Study: 619817
Drug: Carmustine, fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carmustine, fluorouracil, and spironolactone (three-drug regimen)
Study: 619817
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (carmustine, fluorouracil, spironolactone)
Study: 20949623
Drug: Quadrivalent HPV6/11/16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV6/11/16/18 vaccine
Study: 15206665
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, and/or 10-mg nicotine inhaler)
Study: 11409480
Drug: Methotrexate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25 mg, n=9)
Study: 8201564
Drug: Collagen shields
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen shields saturated with an antibiotic and a steroid placed in 90 eyes postoperatively
Study: 8201564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the same drugs through a peribulbar/retrobulbar injection in 93 eyes
Study: 3322763
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (Euthyrox)
Study: 3322763
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (L-Thyroxin Henning)
Study: 3322763
Drug: Preparation C
Normalized name: other nasal preparation combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation C (Levothyroxine, enos)
Study: 23949727
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL contrast medium (G30)
Study: 23949727
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL contrast medium (G40)
Study: 23949727
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL contrast medium (G50)
Study: 23949727
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL contrast medium (G60)
Study: 23949727
Drug: 70 mL
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mL contrast medium (G70)
Study: 20434204
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg daily (n = 18)
Study: 12584827
Drug: Conventional liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional liver protecting treatment
Study: 10512280
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL epidural saline flush
Study: 10512280
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL epidural saline flush
Study: 3510285
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose metoclopramide
Study: 3510285
Drug: Intravenous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high-dose metoclopramide
Study: 17263269
Drug: 20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group A)
Study: 17263269
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group B)
Study: 7250779
Drug: Prostaglandin F2‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2‐alpha gel (2.5 mg, intracervically)
Study: 7250779
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 tablets (1 mg, orally)
Study: 30821167
Drug: Montelukast, fexofenadine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, fexofenadine, and fluticasone nasal spray (Mo-Fex-Flu)
Study: 30821167
Drug: Cetirizine and
Normalized name: Cetirizine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine and fluticasone nasal spray (Cet-Flu)
Study: 28125977
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision support system (CDSS) for medication review
Study: 23702393
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa 0.2 mg/kg every 2 weeks
Study: 23702393
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa 0.1 mg/kg/week
Study: 23702393
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa 0.2 mg/kg/week
Study: 21658010
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) glutamine supplementation, 0.283 g glutamine/kg body weight/24 h for the entire ICU stay
Study: 19701107
Drug: Canfosfamide (400-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canfosfamide (400-1000 mg/m2 IV) with carboplatin (AUC 6 IV) and paclitaxel (200 mg/m2 IV)
Study: 18182447
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg/d
Study: 15330905
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (3 or 5 million units thrice a week) plus ribavirin (1,000-1,200 mg)
Study: 15330905
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (5 million units) plus ribavirin (1,000-1,200 mg)
Study: 15330905
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (3 million units) plus ribavirin (1,000-1,200 mg)
Study: 15330905
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (higher dose) plus ribavirin (1,000-1,200 mg)
Study: 9283926
Drug: Fluoxetine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (in patients with serious physical illness who completed 5 or more weeks)
Study: 7942576
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg dl alpha‐tocopheryl acetate daily for 30 days
Study: 30921234
Drug: Ginger consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger consumption (1600-4000mg daily)
Study: 28504480
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of microneedling and platelet-rich plasma (28 patients, alternative sessions every 2 weeks for a maximum of six sessions)
Study: 21419002
Drug: Conventional antiparkinsonian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiparkinsonian drug therapy alone (Control)
Study: 18211932
Drug: Topical levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical levofloxacin 0.3%
Study: 18211932
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and oral levofloxacin (250 mg)
Study: 18211932
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 400 mg
Study: 18211932
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 250 mg
Study: 16570297
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate (0.8 mg/kg)
Study: 10731187
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol or stanol margarines (2 g added to an average daily portion)
Study: 3937510
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg tablet, twice daily)
Study: 30624586
Drug: Plasma retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma retinol (per 10-μg/dL increment)
Study: 26507194
Drug: Clonidine (150/175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150/175 μg)
Study: 26507194
Drug: Scopolamine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (1.2 mg)